Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.

PubWeight™: 1.46^‹?› | Rank: Top 5%

🔗 View Article (PMID 25718355)

Published in Eur Heart J on February 25, 2015

Authors

Francesco Costa¹, Pascal Vranckx², Sergio Leonardi³, Elisabetta Moscarella⁴, Giuseppe Ando⁵, Paolo Calabro⁴, Giuseppe Oreto⁵, Felix Zijlstra⁶, Marco Valgimigli⁷

Author Affiliations

1: Thoraxcenter, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands Department of Clinical and Experimental Medicine, Policlinico 'G. Martino', University of Messina, Italy.
2: Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Hasselt, Belgium.
3: Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy.
4: Division of Cardiology, Department of Cardiothoracic Sciences, Second University of Naples, Naples, Italy.
5: Department of Clinical and Experimental Medicine, Policlinico 'G. Martino', University of Messina, Italy.
6: Thoraxcenter, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands.
7: Thoraxcenter, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands m.valgimigli@erasmusmc.nl vlgmrc@unife.it.

Associated clinical trials:

Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention (PRODIGY) | NCT00611286

Articles citing this ↘

Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach? Postepy Kardiol Interwencyjnej (2015) 0.80

Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2). PLoS One (2016) 0.75

Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy. Eur Heart J (2015) 0.75

Articles by these authors ⇆

Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet (2015) 4.30

Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. Eur Heart J (2014) 1.46

Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. Am Heart J (2016) 0.79

Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX. J Am Coll Cardiol (2017) 0.78

Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. Int J Cardiol (2015) 0.75